

Title (en)
VACCINES FOR HSV-2

Title (de)
IMPFSTOFFE GEGEN HSV-2

Title (fr)
VACCINS CONTRE LE HSV-2

Publication
EP 3388835 B1 20200401 (EN)

Application
EP 18159552 A 20130516

Priority
• US 201261647764 P 20120516
• US 201261679387 P 20120803
• US 201261714158 P 20121015
• EP 13724492 A 20130516
• US 2013041364 W 20130516

Abstract (en)
[origin: WO2013173590A1] Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects.

IPC 8 full level
G01N 33/569 (2006.01); **C07K 14/005** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61K 39/12** (2006.01); **A61K 39/245** (2006.01)

CPC (source: CN EA EP IL US)
A61K 38/00 (2013.01 - IL); **A61K 39/12** (2013.01 - CN EA EP IL US); **A61K 39/245** (2013.01 - CN EA EP IL US); **A61P 31/20** (2017.12 - EP); **A61P 31/22** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **C07K 14/005** (2013.01 - CN EA EP IL US); **A61K 38/00** (2013.01 - CN EA EP US); **A61K 2039/545** (2013.01 - CN EA EP IL US); **A61K 2039/55572** (2013.01 - CN EA EP IL US); **C12N 2710/16622** (2013.01 - CN EA EP IL US); **C12N 2710/16634** (2013.01 - CN EA EP IL US); **G01N 33/56994** (2013.01 - CN EA)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2013173590 A1 20131121; AU 2013262691 A1 20141127; AU 2013262691 B2 20181220; AU 2019201927 A1 20190411; BR 112014028476 A2 20170801; CA 2873629 A1 20131121; CN 104412108 A 20150311; CN 104412108 B 20170825; CN 107540730 A 20180105; CN 107540730 B 20210716; CY 1120489 T1 20190710; DK 2850431 T3 20180716; EA 034351 B1 20200130; EA 201492110 A1 20150831; EP 2850431 A1 20150325; EP 2850431 B1 20180418; EP 3388835 A1 20181017; EP 3388835 B1 20200401; ES 2673556 T3 20180622; ES 2787455 T3 20201016; HK 1202627 A1 20151002; HR P20181102 T1 20180907; HU E039215 T2 20181228; IL 235633 A0 20150129; IL 235633 B 20190829; IL 267111 A 20190829; IL 267111 B 20210531; JP 2015522540 A 20150806; JP 2018076381 A 20180517; JP 2019194255 A 20191107; JP 6619648 B2 20191211; JP 6790189 B2 20201125; KR 102136433 B1 20200722; KR 20150014500 A 20150206; LT 2850431 T 20180625; MX 2014013921 A 20150605; MX 350274 B 20170831; NZ 701881 A 20161028; PL 2850431 T3 20180928; PT 2850431 T 20180723; RS 57420 B1 20180928; SG 11201407586W A 20141230; SI 2850431 T1 20180831; US 10391164 B2 20190827; US 2014086947 A1 20140327; US 2014127247 A1 20140508; US 2017274066 A1 20170928; US 2020023057 A1 20200123; US 9555099 B2 20170131; US 9895435 B2 20180220; ZA 201408456 B 20160831

DOCDB simple family (application)
US 2013041364 W 20130516; AU 2013262691 A 20130516; AU 2019201927 A 20190320; BR 112014028476 A 20130516; CA 2873629 A 20130516; CN 201380036258 A 20130516; CN 201710598216 A 20130516; CY 181100731 T 20180712; DK 13724492 T 20130516; EA 201492110 A 20130516; EP 13724492 A 20130516; EP 18159552 A 20130516; ES 13724492 T 20130516; ES 18159552 T 20130516; HK 15103101 A 20150326; HR P20181102 T 20180713; HU E13724492 A 20130516; IL 23563314 A 20141111; IL 26711119 A 20190605; JP 2015512841 A 20130516; JP 2018019053 A 20180206; JP 2019133412 A 20190719; KR 20147035363 A 20130516; LT 13724492 T 20130516; MX 2014013921 A 20130516; NZ 70188113 A 20130516; PL 13724492 T 20130516; PT 13724492 T 20130516; RS P20180792 A 20130516; SG 11201407586W A 20130516; SI 201331065 T 20130516; US 201313895858 A 20130516; US 201313895888 A 20130516; US 201615378864 A 20161214; US 201916513311 A 20190716; ZA 201408456 A 20141118